Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis and Cirrhosis, Including Those With Clinical Signs of Portal Hypertension: Interim Results From the Open-Label ASSURE Study With up to 4 Years of Treatment

Conference Reports for NATAP

EASL - European Association
for the Study of the Liver
Barcelona, Spain
May 27-30, 2026


Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis and Cirrhosis, Including Those With Clinical Signs of Portal Hypertension: Interim Results From the Open-Label ASSURE Study With up to 4 Years of Treatment

	EASL 2026 May 26-30 Barcelona Aliya Gulamhusein1,